Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

COPD: Update Bulletin [November 2015]

Product Code:
596200425
Publication Date:
November 2015
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events with the potential to shape the treatment of chronic obstructive pulmonary disorder (COPD). Topics covered include opinions about the potential positives that can be drawn from GSK’s SUMMIT trial, how Novartis’ FLAME trial results could change prescribing practice, what the potential role of closed triple combination products in the treatment of COPD could be, and what barriers could prevent their uptake, what  the key differences between AstraZeneca’s ETHOS and GSK’s IMPACT triple therapy exacerbation trials are, and what role anti-IL-13 mAbs have in COPD.

Key Questions Answered in this Update Bulletin:

  • Can any positives be drawn from GSK’s SUMMIT trial results?
  • How might Novartis’ FLAME trial results change prescribing practice?
  • What is the role of closed triple combination products, and what barriers could prevent their uptake?
  • What are the differences between AstraZeneca’s ETHOS and GSK’s IMPACT triple therapy exacerbation trials?
  • What role do anti-IL-13 mAbs have in COPD, and could they be a valuable add-on treatment for patients who continue to have exacerbations despite standard of care?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved